Here's Why Madrigal Pharmaceuticals Fell 39.4% in November

Here's Why Madrigal Pharmaceuticals Fell 39.4% in November

Source: 
Motley Fool
snippet: 

Impressive results from a potential competitor took the shine off this biotech's experimental NASH treatment.